Trends in Neuro Device Investing


What’s happening in neuro device investing? In a new SVB sub-sector report we cover the private companies that are developing devices to treat neurological diseases, as well as non-neuro diseases in which the therapeutic effect is mediated through the nervous system.

Key insights from the report:

  • Financings increased by over 40 percent and invested equity grew by over 50 percent from 2016 to 2017.
  • Nervous system diseases — including pain, epilepsy and movement disorders, among others — represented the largest disease focus for neuro devices, capturing 40-45 percent of financings in both 2016 and 2017.
  • Significant early-stage investment took place, with 16 Seed and Series A financings raising more than $10 million each.

Download the report to learn more

About the Author

Bill Sideris is a Vice President with SVB’s northeast Medical Device and HealthTech practice, where he provides comprehensive financial products and services as well as flexible lending solutions to clients at every stage of development. Previous to this role, he was part of SVB Securities, performing valuations and advising Healthcare and Life Sciences clients on their M&A strategy. Prior to joining SVB, Bill spent time as an R&D Engineer, developing medical devices for ophthalmic and cardiovascular indications in both Fortune 500 and start-up organizations.

Bill graduated with a Professional Doctorate degree in engineering from the Technical University of Delft and a Master of Science degree in biomedical engineering from the University of Houston.